SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genaissance Pharmaceuticals (GNSC)
An SI Board Since September 2000
Posts SubjectMarks Bans Symbol
183 6 0 GNSC
Emcee:  Jim Oravetz Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
58If you read the FDL0215021.pdf document(linked in my last post), on page 12 it sJim Oravetz-3/21/2002
57anyone has any idea that whether their technology works ???farkarooski-3/20/2002
56genaissance.com 4 min video that shows the basis for their technology. The BIG Jim Oravetz-3/20/2002
55>>First glove to fall??<< Apparently, looks like another block justtuck-3/20/2002
54Big block. Looks like it was worked down, as we used to occasionally attribute scaram(o)uche-3/19/2002
53"The state in conjunction with the private industry and academic organizatiJim Oravetz-3/18/2002
52Let's hope they look smart in a bit. This stock is getting slaughtered. Ifscaram(o)uche-3/18/2002
51Seems to be an instrumentality of the state of Connecticut, operating as a venttom pope-3/18/2002
501. Name of Reporting Persons: Connecticut Innovations, Incorporated scaram(o)uche-3/18/2002
49As of February 15, 2002, we had processed in excess of 5,300 pharmaceutically rescaram(o)uche-3/7/2002
48HAP-CLOZAPINE: HAP MARKER DISCOVERY STUDY. We intend to initiate a study designscaram(o)uche-3/7/2002
47HAP-STATIN: STRENGTH TRIALS (STATIN RESPONSE EXAMINED BY GENETIC HAP MARKERS). scaram(o)uche-3/7/2002
46OUR COMMERCIAL PROGRAMS HAP PARTNERSHIP PROGRAM We have developed a prscaram(o)uche-3/7/2002
4510-K is out, looks like STRENGTH I results are still expected before the end of scaram(o)uche-3/7/2002
44The Pharmacogenomics Journal (Abstract in Advance of Print) Pharmacogenomic-guiscaram(o)uche-2/24/2002
43Pharmacokinetics and Pharmacogenomics: Advancing Understanding One Step at a Timmichael_f_murphy-2/19/2002
42Waiting in the Wings: Update on Investigational Antiretrovirals Mike Youle MB, Cmichael_f_murphy-2/19/2002
41NEW HAVEN, Conn., Feb. 6 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, nigel bates-2/6/2002
40220K shares........ FILED: 1/25/2002 12:00 AM FILER: BANK JULIUS BAER & CO scaram(o)uche-2/4/2002
39NEW HAVEN, Conn., Feb. 1 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, nigel bates-2/1/2002
38Genaissance Pharmaceuticals and Biogen Sign Pharmacogenomics Collaboration For Rnigel bates-2/1/2002
37Genaissance Pharmaceuticals Announces First Drug Development Candidates NEW HAVnigel bates-1/24/2002
36NEW HAVEN, Conn., Jan. 15 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals,nigel bates-1/15/2002
35("financial terms were not disclosed...") Genaissance Pharmaceuticalsnigel bates-12/11/2001
34Article from Drug Discovery & Development on Genaissance, with emphasis on ttuck-11/7/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News